Immunosuppressive Strategies that are Mediated by Tumor Cells

Annual Review of Immunology - Tập 25 Số 1 - Trang 267-296 - 2007
Gabriel A. Rabinovich1, Dmitry I. Gabrilovich2, Eduardo M. Sotomayor2
1Division of Immunogenetics, Hospital de Clínicas “José de San Martín,” University of Buenos Aires, Buenos Aires, Argentina;
2Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL 33612

Tóm tắt

Despite major advances in understanding the mechanisms leading to tumor immunity, a number of obstacles hinder the successful translation of mechanistic insights into effective tumor immunotherapy. Such obstacles include the ability of tumors to foster a tolerant microenvironment and the activation of a plethora of immunosuppressive mechanisms, which may act in concert to counteract effective immune responses. Here we discuss different strategies employed by tumors to thwart immune responses, including tumor-induced impairment of antigen presentation, the activation of negative costimulatory signals, and the elaboration of immunosuppressive factors. In addition, we underscore the influence of regulatory cell populations that may contribute to this immunosuppressive network; these include regulatory T cells, natural killer T cells, and distinct subsets of immature and mature dendritic cells. The current wealth of preclinical information promises a future scenario in which the synchronized blockade of immunosuppressive mechanisms may be effective in combination with other conventional strategies to overcome immunological tolerance and promote tumor regression.

Từ khóa


Tài liệu tham khảo

10.1038/86297

10.1016/S0065-2776(06)90002-9

10.1146/annurev.immunol.22.012703.104803

10.1146/annurev.immunol.24.021605.090733

10.1016/S1074-7613(00)80028-X

10.1615/CritRevOncog.v7.i5-6.30

10.1002/eji.1830261119

10.1073/pnas.95.3.1178

Cuenca A, 2003, Cancer Res., 63, 9007

Morgan DJ, 1998, J. Immunol, 160, 643, 10.4049/jimmunol.160.2.643

10.1084/jem.20030590

10.1038/nature03954

10.1038/9525

10.1158/0008-5472.CAN-04-3337

10.1146/annurev.immunol.21.120601.141135

10.1182/blood-2005-07-3014

10.1016/j.ccr.2005.01.027

10.1182/blood-2005-07-2737

10.1073/pnas.96.5.2233

10.4049/jimmunol.165.12.6731

10.4049/jimmunol.166.4.2863

10.4049/jimmunol.172.11.6558

10.1126/science.1900952

10.1182/blood.V98.4.1070

10.1146/annurev.immunol.21.120601.141040

10.1084/jem.20020861

10.1126/science.1073514

10.1006/smim.1996.0035

10.1016/S0002-9440(10)63238-5

10.1038/nm1096-1096

10.1038/nm976

10.1038/nm1325

10.1016/S1074-7613(03)00232-2

10.1172/JCI26169

10.1073/pnas.0509784103

10.1182/blood-2004-01-0027

10.1016/S0065-2776(06)90008-X

10.1016/S1074-7613(00)80284-8

10.1073/pnas.96.20.11476

10.1084/jem.190.3.355

10.1073/pnas.1533209100

10.1038/nbt1007

10.1038/10503

10.1038/10495

10.1038/90942

10.4049/jimmunol.176.2.974

Igney FH, 2002, J. Leukoc. Biol, 71, 907, 10.1189/jlb.71.6.907

10.1016/j.semcancer.2005.07.008

10.1038/ni1102-999

10.1007/s00262-004-0593-x

10.1038/nm0904-887

10.1016/S0065-2776(08)60911-6

10.1038/nm999

10.1034/j.1600-065X.2002.18809.x

10.1016/S1357-4310(99)01451-3

10.1172/JCI116249

10.1073/pnas.86.17.6719

10.1126/science.1465616

10.4049/jimmunol.174.4.1830

10.1146/annurev.med.56.082103.104549

10.1146/annurev.immunol.24.021605.090737

10.1073/pnas.87.4.1486

10.1038/nm1001-1118

10.1016/j.ccr.2005.10.012

10.4049/jimmunol.174.9.5215

10.1038/82771

10.4049/jimmunol.173.3.1731

10.4049/jimmunol.173.7.4352

10.1038/nm0198-043

10.1189/jlb.0705358

10.4049/jimmunol.175.9.5885

10.1038/nri1703

10.1016/j.ccr.2004.08.012

10.1126/science.271.5256.1734

10.1073/pnas.0830997100

10.1172/JCI27745

10.1002/j.1460-2075.1992.tb05481.x

10.1016/S1074-7613(00)80089-8

10.1084/jem.192.7.1027

10.1038/nm0902-1039c

10.1073/pnas.192461099

10.1158/0008-5472.CAN-03-3259

10.1038/nm863

10.1038/nature04444

10.1084/jem.20050072

10.1038/ni944

10.1084/jem.20050930

10.1146/annurev.immunol.18.1.367

10.1126/science.281.5380.1191

10.1038/nm934

10.1038/nm1196

10.1038/82712

10.1126/science.274.5291.1363

10.1038/85395

10.1084/jem.20011624

10.1007/s00262-005-0680-7

10.1158/0008-5472.CAN-05-1462

10.1126/science.282.5394.1714

Chappell DB, 1999, Cancer Res, 59, 59

10.1038/sj.bjc.6602360

10.1158/0008-5472.CAN-05-3204

Giovarelli M, 1999, J. Immunol., 163, 4886, 10.4049/jimmunol.163.9.4886

10.1016/S0960-9822(01)00199-3

10.1038/11383

10.1158/0008-5472.CAN-04-4395

10.1093/glycob/cwl025

10.1038/nrc1527

10.1038/378736a0

10.1074/jbc.M409752200

10.4049/jimmunol.165.7.3722

10.1084/jem.190.3.385

10.1016/S1471-4906(02)02232-9

10.1016/S1535-6108(04)00024-8

10.1200/JCO.2005.02.0206

10.4049/jimmunol.173.6.3825

Fukumori T, 2003, Cancer Res., 63, 8302

10.1038/ni1271

10.1038/35055582

10.1146/annurev.immunol.21.120601.141122

10.1038/nrc1586

10.1038/nm1093

Shimizu J, 1999, J. Immunol, 163, 5211, 10.4049/jimmunol.163.10.5211

Onizuka S, 1999, Cancer Res, 59, 3128

10.1084/jem.20041130

10.1038/nri1867

10.1126/science.1078231

10.1126/science.1113401

10.1084/jem.20042167

10.1172/JCI23215

10.1111/j.1365-2567.2006.02348.x

10.1002/eji.200425093

10.1146/annurev.immunol.20.100301.064828

10.1016/j.immuni.2004.06.011

10.1038/nri746

10.1146/annurev.immunol.18.1.767

10.1016/S0092-8674(01)00455-X

Ishida T, 1998, J. Immunol, 161, 4842, 10.4049/jimmunol.161.9.4842

Almand B, 2000, Clin. Cancer Res., 6, 1755

Hoffmann TK, 2002, Clin. Cancer Res, 8, 1787

10.1593/neo.05442

Troy AJ, 1998, Clin. Cancer Res, 4, 585

10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3

Nestle FO, 1997, Am. J. Pathol, 150, 641

10.1002/(SICI)1097-0215(19970807)72:4<619::AID-IJC12>3.0.CO;2-6

Gabrilovich DI, 1997, Clin. Cancer Res, 3, 483

10.1084/jem.20021598

10.1038/ni1141

10.1038/nm1201-1339

Hartmann E, 2003, Cancer Res., 63, 6478

10.1002/path.1344

10.1172/JCI200421583

10.4049/jimmunol.171.4.1652

10.1093/intimm/dxh140

10.1038/ni1003

10.1038/ni1130

Steinbrink K, 1997, J. Immunol, 159, 4772, 10.4049/jimmunol.159.10.4772

10.4049/jimmunol.164.5.2405

10.1016/S1074-7613(03)00113-4

10.1007/s00262-002-0280-8

10.1189/jlb.0103010

10.4049/jimmunol.172.1.464

10.1084/jem.20022227

Bronte V, 1998, J. Immunol., 161, 5313, 10.4049/jimmunol.161.10.5313

10.4049/jimmunol.166.9.5398

10.1158/0008-5472.CAN-03-1715

10.4049/jimmunol.172.2.989

10.4049/jimmunol.175.7.4583

10.1158/0008-5472.CAN-05-1299

10.4049/jimmunol.170.1.270

10.4049/jimmunol.174.8.4880

10.4049/jimmunol.166.1.678

10.1158/0008-5472.CAN-03-2646

Schmielau J, 2001, Cancer Res, 61, 4756

10.1182/blood-2003-12-4392

10.1038/nrc1167

10.1038/nri1150

10.1038/ni1205-1207

Thông tin
Thông tin xuất bản

Annual Review of Immunology

Tập 25 Số 1

267-296

Thông tin tác giả